After encouraging results in an attempt to revive brain dead subjects, Revita Life Sciences — a biotechnology company focused on translational regenerative therapeutic applications, has announced that it will continue to advance to next phase of its novel, multi-modality clinical intervention in the state of brain death in humans as an attempt to reverse the state of brain death.
“We have proactively continued to advance our multi-modality protocol as an extended treatment before extubation in an attempt to reverse the state of brain death. This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns”, said Pranjal Agrawal, CEO, Revita Life Sciences.
The company is also in process of publishing initial retrospective results, as well ongoing early results, in a peer reviewed journal. These initial findings will prove invaluable to the future evolution of the program, as well as in progressing the development multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans, said Dr. Himanshu Bansal, chief scientific officer Revita Life Sciences and director, MOTHER CELL.
